- Stocks
- Healthcare
- NASDAQ: COLL

Price (delayed)

$22.37

Market cap

$788.49M

P/E Ratio

18.49

Dividend/share

N/A

EPS

$1.21

Enterprise value

$897.47M

Collegium Pharmaceutical's gross profit has surged by 68% YoY and by 9% QoQ

The gross margin has surged by 57% year-on-year and by 6% since the previous quarter

The equity is up by 21% year-on-year but it is down by 9% since the previous quarter

COLL's debt is up by 10% since the previous quarter

Sector: Healthcare

Industry: Drug Manufacturers - Specialty & Generic

Website: http://www.collegiumpharma.com/

What are the main financial stats of COLL

Market
Valuations
Earnings

Shares outstanding

35.25M

Market cap

$788.49M

Enterprise value

$897.47M

Price to earnings (P/E)

18.49

Price to book (P/B)

4.57

Price to sales (P/S)

2.43

EV/EBIT

12.4

EV/EBITDA

12.2

EV/Sales

2.79

Revenue

$321.23M

EBIT

$72.39M

EBITDA

$73.54M

Free cash flow

$114.63M

Per share
Balance sheet
Liquidity

EPS

$1.21

Free cash flow per share

$3.28

Book value per share

$4.89

Revenue per share

$9.19

TBVPS

$9.35

Total assets

$646.07M

Total liabilities

$476.03M

Debt

$294.32M

Equity

$170.04M

Working capital

$66.14M

Debt to equity

1.73

Current ratio

1.29

Quick ratio

1.21

Net debt/EBITDA

1.48

Margins
Efficiency
Dividend

EBITDA margin

22.9%

Gross margin

61.2%

Net margin

13.1%

Operating margin

22.5%

Return on assets

6.5%

Return on equity

24.5%

Return on invested capital

42.2%

Return on capital employed

17.4%

Return on sales

22.5%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Collegium Pharmaceutical stock price performed over time

Intraday

0.36%

1 week

-4.28%

1 month

-2.48%

1 year

23.93%

YTD

11.68%

QTD

-5.61%

How have Collegium Pharmaceutical's revenue and profit performed over time

Revenue

$321.23M

Gross profit

$196.45M

Operating income

$72.36M

Net income

$41.96M

Gross margin

61.2%

Net margin

13.1%

Collegium Pharmaceutical's gross profit has surged by 68% YoY and by 9% QoQ

The gross margin has surged by 57% year-on-year and by 6% since the previous quarter

The net income has soared by 57% from the previous quarter

COLL's net margin has surged by 52% since the previous quarter

What is Collegium Pharmaceutical's growth rate over time

What is Collegium Pharmaceutical stock price valuation

P/E

18.49

P/B

4.57

P/S

2.43

EV/EBIT

12.4

EV/EBITDA

12.2

EV/Sales

2.79

Collegium Pharmaceutical's EPS has soared by 55% from the previous quarter

The equity is up by 21% year-on-year but it is down by 9% since the previous quarter

The price to book (P/B) is 12% lower than the 5-year quarterly average of 5.2 but 11% higher than the last 4 quarters average of 4.1

COLL's price to sales (P/S) is 97% lower than its 5-year quarterly average of 80.3 but 6% higher than its last 4 quarters average of 2.3

The revenue is up by 8% year-on-year and by 3.6% since the previous quarter

How efficient is Collegium Pharmaceutical business performance

The company's return on assets has surged by 55% QoQ

The ROE has soared by 50% QoQ

The ROIC has grown by 24% from the previous quarter

Collegium Pharmaceutical's ROS has increased by 24% from the previous quarter

What is COLL's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for COLL.

How did Collegium Pharmaceutical financials performed over time

Collegium Pharmaceutical's total assets is 36% more than its total liabilities

The quick ratio rose by 44% year-on-year and by 11% since the previous quarter

The current ratio has increased by 40% year-on-year and by 11% since the previous quarter

COLL's debt is 73% greater than its equity

The debt to equity rose by 21% QoQ but it fell by 18% YoY

The equity is up by 21% year-on-year but it is down by 9% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.